Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers

Boehringer Ingelheim40 enrolled

Overview

The objective of the current study is to investigate the relative bioavailability of two different batches of a 2.5 mg linagliptin / 1000 mg metformin fixed dose combination tablet (FDC).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Linagliptin/Metformin (standard batch)DRUG

Fixed dose combination tablet

Linagliptin/Metformin (side batch)DRUG

Fixed dose combination tablet

Eligibility

Sex: ALLMin age: 21 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion criteria: 1. Healthy males and females according to the following criteria: Based upon a complete medical history, including physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests 2. Age 21 to 50 years (incl.) 3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.) 4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation Exclusion criteria: 1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance 2. Any evidence of a clinically relevant concomitant disease 3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 4. Surgery of the gastrointestinal tract (except appendectomy) 5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 6. History of relevant orthostatic hypotension, fainting spells or blackouts 7. Chronic or relevant acute infections 8. History of relevant allergy or hypersensitivity (including allergy to drug or its excipients) 9. Intake of drugs within one month or less than 10 half-lives of the respective drug prior to first study drug administration 10. Participation in another trial with an investigational drug within 2 months prior to administration or during the trial 11. Smoker (more than 10 cigarettes or 3 cigars 3 pipes daily) 12. Alcohol abuse (average consumption of more than 20 g/day in females and 30 g/day in males) 13. Drug abuse 14. Blood donation (more than 100 mL within four weeks prior to day 1 of visit 2) 15. Any laboratory value outside the reference range that is of clinical relevance 16. Inability to comply with dietary regimen of trial site For female subjects of childbearing potential only: 17. Positive pregnancy test, pregnancy or planning to become pregnant 1 month before study or within 2 months after study completion 18. No adequate contraception 1 month before study and until 2 month after study completion, e.g. not any of the following: implants, injectables, combined hormonal contraceptives, hormonal IUD (intrauterine device), sexual abstinence for at least 1 month prior to first study drug administration, vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (including hysterectomy). Females, who do not have a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to use an additional barrier method (e.g. condom). 19. Lactation

Locations (1)

1288.6.1 Boehringer Ingelheim Investigational Site

Ingelheim, Germany